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Background: Continuous, non-invasive assessment of alveolar ventilation achieved by transcu-
taneous PCO2 (PtcCO2) monitoring is clearly superior to intermittent, invasive blood gas anal-
yses in patients receiving nocturnal non-invasive positive pressure ventilation (NPPV), but the
reliability and accuracy of PtcCO2-monitoring is still disputed. The present study was aimed at
investigating the capability of modern PtcCO2-monitoring to reliably assess alveolar ventilation
during nocturnal NPPV.
Methods: Capillary blood gas measurements (11pm, 2am, 5am and 7am) and 8 h of continuous
PtcCO2-monitoring using three of the latest generation devices (SenTec Digital Monitor, Radi-
ometer TCM4-TINA and Radiometer TOSCA500) were performed during polysomnography-
proven sleep studies in 24 patients receiving NPPV (15 with COPD, 9 with restrictive disorders).
Results: The technical calibration drift for SenTec DM, TCM4-TINA and TOSCA500 was 0.1, 0.4
and 0.5 mmHg/h, respectively. Bland-Altman method comparison of PaCO2/drift-uncor-
rected PtcCO2 revealed a mean bias (limits of agreement) of 1.0 (4.7 to 6.7), 1.5 (15.6
to 12.5) and 0.8 (6.8 to 8.3) mmHg, respectively. Continuous overnight PtcCO2-monitoring
detected variations in alveolar ventilation, with median ranges of 12.3 (10.7e14.5) mmHganalysis; BE, base excess; BMI, body mass index; CI, confidence interval; COPD, chronic obstructive
e; EPAP, expiratory positive airway pressure; FEV1, forced expiratory volume in 1 s; FVC, forced vital
; HRF, hypercapnic respiratory failure; IPAP, inspiratory positive airway pressure; LTOT, long-term
ormality test failed; NREM, non-rapid eye movement sleep; NPPV, non-invasive positive pressure
carbon dioxide; PaCO2, arterial partial pressure of carbon dioxide; PetCO2, end-tidal partial pressure
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144 J.H. Storre et al.for SenTec DM, 14.5 (12.5e17.0) mmHg for TCM4-TINA and 11.5 (11.0e13.0) mmHg for TOS-
CA500 (RM-ANOVA, p < 0.001). The four capillary PaCO2 values ranged by a median of 6.3
(4.7e9.7) mmHg.
Conclusions: Modern PtcCO2-monitoring is reliable, accurate and robust. Since PtcCO2-moni-
toring is also non-invasive, does not disrupt sleep quality and provides a more complete picture
of alveolar ventilation than intermittent capillary PaCO2, PtcCO2-monitoring should become
the preferred technique for assessing alveolar ventilation during nocturnal NPPV.
Trial Registration: DRKS00000433 at http://apps.who.int/trialsearch/default.aspx.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Monitoring the partial pressure of carbon dioxide (PCO2) is
an essential means of assessing alveolar ventilation in
patients with chronic hypercapnic respiratory failure (HRF),
particularly in those receiving nocturnal non-invasive posi-
tive pressure ventilation (NPPV), which is aimed at
improving for improved alveolar hypoventilation and sleep
quality.1e12 Although the measurement of arterial PCO2
(PaCO2) is regarded as the gold standard technique for PCO2
assessment3,13e16 it is an invasive and painful method
requiring an arterial blood gas analysis (ABG) or, alterna-
tively, a blood sample from the arterialized ear lobe.16
Importantly, it also disrupts a patient’s sleep structure if
performed during the night, and only reflects a snap shot of
the potentially varying ventilatory status of patients with
chronic HRF.14,15,17e20 Although the relevance of PaCO2
assessment is undisputed for several conditions, including
acute respiratory failure,21 non-invasive and continuous
PCO2 monitoring is clearly preferable for monitoring the
varying status of alveolar ventilation during sleep.2,5,9,15
In general, two different techniques for continuous non-
invasive PCO2 monitoring have been introduced into clinical
practice; namely, end-tidal (PetCO2) and transcutaneous
(PtcCO2) measurements.
9,17,20 However, according to an
early study, neither PetCO2 nor PtcCO2-monitoring provided
an accurate reflection of PaCO2 during sleep.
15 PetCO2
monitoring is known to have limitations in parenchymal
lung disease and, importantly, also in the case of air
leakage around the mask or via mouth, which regularly
occurs in NPPV patients.3,7,15,17,20,22,23 In contrast, PtcCO2-
monitoring is independent from both air leakage and the
underlying disease, and has been shown to be more reliable
than PetCO2 monitoring in different conditions.
24e27
An important limitation of PtcCO2-monitoring is the
reported occurrence of technical PtcCO2 drifts, which can
be particularly momentous if monitoring is performed over
a period of several hours or throughout the whole night.5,17
Interestingly, more recent daytime studies have reported
a substantial improvement in PtcCO2 drifts, likely due to
technical refinements in PtcCO2-monitoring
13,14,28e34;
however, overnight studies using modern techniques are
still lacking.
Therefore, if continuous and non-invasive overnight
PtcCO2-monitoring are determined to be just as accurate as
invasive, intermittent PaCO2-measurements, this technique
could become the preferred means for monitoring
nocturnal alveolar ventilation in chronic HRF patients.
Hence, the present study aims to assess the accuracy of
modern technologies designed for PtcCO2-monitoring inpatients receiving overnight NPPV. Some of the results of
these studies have been previously reported in the form of
an abstract.35
Materials and methods
The study protocol was approved by the Institutional
Review Board for Human Studies at the Albert-Ludwigs
University, Freiburg, Germany, and was performed in
accordance with the ethical standards laid down in the
Declaration of Helsinki. Written informed consent was
obtained from all subjects.
Patients
Stable NPPV patients without evidence of acute respiratory
failure and severe obesity (BMI > 35 kg/m2) were included
in this study23,36 [for details see Supplementary Material].
Measurements
Lung function parameters (Masterlab-Compact Labor;
Jaeger; Hochberg, Germany) were assessed in accordance
with international guidelines.37e39 Daytime ABG samples
(AVL OMNI; Roche Diagnostics GmbH; Graz, Austria) were
taken simultaneously from both the radial artery and the
arterialized earlobe during spontaneous breathing at 4pm.
Patients were excluded from the study if the ABG samples
each taken from the artery and the arterialized earlobe
showed a PaCO2 difference >2.5 mmHg.
16
PtcCO2 was monitored using the latest generation of
three different devices, with the sensor temperature set to
42 C20,31,34,40: 1) SenTec Digital Monitor (SenTec DM,
Software 06.21.1, V04.04.04; SenTec AG; Therwil,
Switzerland), 2) TCM4-TINA (Version 2.12; Radiometer
Medical ApS; Brønshøj, Denmark) and 3) TOSCA500 (Main
1.30; Radiometer Medical ApS). Full polysomnography
(SOMNOscreen plus; Somnomedics GmbH; Randersacker,
Germany) was performed according to guidelines41e43 [for
details see Supplementary Material].
Study design
All PtcCO2-monitors were activated and calibrated 4 h prior
to the sleep study. For nocturnal measurements the sensors
of all three PtcCO2-monitors were placed 5 cm below either
the right or left clavicle with fixation rings. All three sensors
were placed under the same clavicle. Lateral to medial
positioning of the three sensors was chosen in a randomized
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tored continuously with all devices simultaneously from
10.30pm to 7am, while sleep studies were also performed.
Capillary ABG samples were intermittently taken at 11pm,
2am, 5am and 7am. Drift correction was performed
immediately after the conclusion of measurements at 7am
[for details see Supplementary Material].
Statistics
Statistical analysis was performed using a statistical soft-
ware package (Sigma-Plot, version 11; Systat Software, Inc;
Point Richmond, CA). Normally distributed data are pre-
sented as mean  standard deviation (SD) (Kolmogor-
oveSmirnov test), while non-normally distributed data are
presented as median with interquartile range.
Comparison between different patient groups was per-
formed using the t-test for normally distributed data and
the ManneWhitney Rank Sum Test for not normally
distributed data. The difference in technical calibration
drifts14 between SenTec DM, TCM4-TINA and TOSCA500 at
the end of overnight PtcCO2-monitoring was calculated
using the Friedman Repeated Measures Analysis of Variance
(RM-ANOVA) on Ranks. The difference in the overnight PCO2
range (maximal minus minimal value) between PaCO2 and
drift-uncorrected PtcCO2 by SenTec DM, TCM4-TINA and
TOSCA500 was calculated using the Friedman Repeated
Measures Analysis of Variance (RM-ANOVA) on Ranks.
Correlation analysis44 and agreement in method
comparison45 between PaCO2 and PtcCO2 was performed
using the methods described by Bland and Altman for each
monitor, respectively. A difference of7.5 mmHg
between PtcCO2 and PaCO2 has been deemed acceptable.
28
Since previous studies reported a lower accuracy of PtcCO2 in
hypercapnic PaCO2-ranges,
13,32,33 an analysis of method
agreement for all hypercapnic PtcCO2/PaCO2epairs of
values (defined as PaCO2 >50 mmHg) was performed.
Statistical significance was assumedwith a p-value of<0.05.
Results
A total of thirty consecutive patients were screened. Four
of them showed a >2.5 mmHg discrepancy between
daytime arterial and capillary blood gas analysis, as defined
above. Two patients dropped out due to technical problems
caused by staff. Therefore, 24 patients completed the
study (Table 1). Fifteen patients had an underlying diag-
nosis of COPD. Nine patients had restrictive ventilatory
disorders (non-COPD) due to amyotrophic lateral sclerosis
(N Z 3), pulmonary fibrosis, neuropathy, obesity hypo-
ventilation syndrome, kyphoscoliosis, pneumectomy and
congenital central hypoventilation syndrome (N Z 1,
respectively). Twenty-one patients received high-intensity
NPPV in the assist/controlled mode as previously
described,11,12 and three patients received pressure
support ventilation (Table 2). Results of polysomnography
are presented in Table 2. Technical drift analysis and
results of continuous overnight PtcCO2-monitoring are given
in Table 3. Here, the SenTec DM produced a smaller tech-
nical calibration drift after 8 h compared to TCM4-TINA and
TOSCA500, while TCM4-TINA and TOSCA500 did not differ(RM-ANOVA, p < 0.001; Table 3). The mean technical drift
per hour was calculated to be 0.1 mmHg for the SenTec DM,
0.4 mmHg for the TCM4-TINA and 0.5 mmHg for the
TOSCA500, respectively. Results of correlation analysis and
method comparison by Bland and Altman of PtcCO2/
PaCO2epairs are summarized in Table 4. Device related
plots of method comparison are assessable for both drift-
corrected and drift-uncorrected PtcCO2/PaCO2epairs in the
Supplementary Material Figs. 1e6.
Method comparison in the subgroup of PtcCO2/PaCO2-
pairs with PaCO2 >50mmHg (N Z 32) revealed for drift-
uncorrected values a mean bias (limits of agreement) of 2.1
(3.1 to 7.3) mmHg for the SenTec DM, 1.3 (15.7 to
13.2) mmHg for the TCM4-TINA, and 3.2 (4.6 to 11.0)
mmHg for the TOSCA500. For drift-corrected values a mean
bias of 2.4 (3.1 to 8.0) mmHg for the SenTec DM, 2.7
(14.2 to 8.8) mmHg for the TCM4-TINA, and 0.5 (6.7 to
7.8) mmHg for the TOSCA500 was calculated.
The four overnight capillary PaCO2 values ranged by
a median of 6.3 (4.7e9.7) mmHg, while the corresponding
simultaneously monitored values for PtcCO2 values ranged
by a median of 5.8 (3.4e7.6) mmHg for the SenTec DM, 9.0
(6.0e12.0) mmHg for the TCM4-TINA and 6.5 (4.5e7.5)
mmHg for the TOSCA500 (RM-ANOVA, p Z 0.003; Fig. 1).
Continuous overnight PtcCO2 measurements revealed
carbon dioxide ranges of 12.3 (10.7e14.5) mmHg for the
SenTec DM, 14.5 (12.5e17.0) mmHg for the TCM4-TINA and
11.5 (11.0e13.0) mmHg for the TOSCA500 (RM-ANOVA,
p < 0.001; Fig. 2). The overnight trend for PaCO2 and
PtcCO2 values in a 34-year old patient with congenital
central hypoventilation syndrome is displayed in Fig. 3.
Of the twenty-four patients measured, there was only
one case for each PtcCO2-monitor in which complete
disconnection of PtcCO2-Sensors occurred, thus requiring
reattachment to the skin. Short-term intervals of missing
data due to sensor detachment from the skin (but without
need for sensor-replacement) were observed once each
with the SenTec DM and TOSCA500 (Fig. 3), and three times
with the TCM4-TINA.Discussion
This is the first study analyzing the usefulness of modern
techniques developed for non-invasive and continuous
PtcCO2-monitoring when applied during an 8-h-overnight
period in patients receiving nocturnal NPPV to treat chronic
HRF. There are two major findings arising from this study.
Firstly, all PtcCO2-monitors investigated showed low
technical drifts during the complete sleep study. Here, the
minimal and maximal technical calibration drift was
observed using the SenTec DM and TOSCA500, with an hourly
PtcCO2 valueof 0.1mmHgand0.5mmHg, respectively.This
is in contrast to previous findings, where the technical drift
was reported to be considerably higher, with values of
1.3 mmHg14 and 1 mmHg32 per hour. For this reason, the
current data suggest a notable technical improvement in
modern PtcCO2-monitoring, with a substantial reduction in
technical drift that allows reliable clinical application, even
over long periods of 8 h.17
Secondly, when comparing nocturnal PtcCO2-monitoring
with the gold standard PaCO2-measurements, the overall
Table 1 Demographic data, lung function parameters and arterial daytime blood gases. Values for mean  standard deviation
or median with interquartile range are given.
COPD (N Z 15) NON-COPD (N Z 9) Difference of mean 95% CI p-value
Male/female 10/5 6/3
Age (years) 63.0 (56.3e71.5) 60.0 (45.0e70.0) NF 0.283
BMI (kg/m2) 25.3  5.5 27.2  4.5 2.6 to 6.4 0.401
NPPV use (months) 6.0 (2.0e15.8) 90.0 (18.5e111.8) NF 0.003
FEV1 (% predicted) 22.2 (20.2e44.9) 45.6 (38.5e56.4) NF 0.042
FVC (% predicted) 53.7  19.8 50.8  15.0 19.6 to 13.9 0.724
FEV1/FVC (%) 50.0  13.1 83.6  8.7 22.8 to 44.5 0.001
RV (% predicted) 257.7 (165.4e299.2) 91.9 (81.0e122.1)* NF 0.002
TLC (% predicted) 113.1  22.1 64.1  8.9* 67.2 to 30.6 <0.001
LTOT (L/min) 2.0 (1.0e3.0) 0.0 (0.0e1.1) NF 0.067
pH 7.41  0.03 7.42  0.02 0.02 to 0.03 0.519
PaCO2 (mmHg) 47.7  7.8 45.1  7.3 9.4 to 4.2 0.430
PaO2 (mmHg) 76.3 (60.6e94.1) 75.2 (69.8e85.4) NF 0.975
HCO-3 (mmol/l) 29.5  3.2 28.6  4.4 4.2 to 2.4 0.579
BE (mmol/l) 4.4  2.2 3.9  3.5 3.0 to 2.0 0.705
BE Z base excess, BMI Z body mass index, CI Z confidence interval, FEV1 Z forced expiratory volume in 1 s, FVC Z forced vital
capacity, HCO-3 Z standard bicarbonate, LTOT Z long-term oxygen therapy, NF Z normality test failed, PaCO2 Z arterial partial
pressure of carbon dioxide, PaO2 Z arterial partial pressure of oxygen, RV Z residual volume, TLC Z total lung capacity. *n Z 8.
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a useful means of monitoring nocturnal alveolar ventila-
tion. Previous studies have already compared these two
techniques in NPPV patients13,31e33; however, most studies
were performed during the day and an entire sleep studyTable 2 NPPV settings and polysomnography during nocturnal
interquartile range are given.
COPD (N Z 15) NON-C
NPPV settings
Mask: nasal/full face 6/9 6/3
Oxygen flow (L/min) 3.0 (2.0e3.0) 0.0 (0.
IPAP (mbar) 28.0 (24.3e29.5) 20.0 (1
EPAP (mbar) 4.0 (4.0e5.0) 4.0 (1.
RRset (/min) 20.0 (18.0e20.0) 18.0 (1
Inspiratory Time (sec) 1.0 (1.0e1.0)a 1.3 (1.
Polysomnography
TST (min) 283.1  108.1 284.4
Sleep efficiency (%) 78.6 (62.9e82.0) 83.9 (6
NREM 1 (% TST) 18.5 (10.2e22.9) 24.7 (8
NREM 2 (% TST) 47.5  19.5 49.5 
NREM 3 þ 4 (% TST) 15.2  10.0 13.4 
REM (% TST) 13.1  9.0 9.5 
Arousals (/h) 19.4  15.3 19.7 
Apnea-Hypopnea-Index (/h) 0.8 (0.3e6.7) 1.8 (0.
Mean SaO2 (%) 91.7  3.1 92.3 
Desaturation-Index (/h) 1.4 (0.8e5.7) 1.3 (0.
Heart rate (/min) 73.5  10.2 68.9 
EPAP Z expiratory positive airway pressure, IPAP Z inspiratory pos
invasive positive pressure ventilation, NREM Z non-rapid eye move
respiratory rate (including back-up frequency in pressure support mo
a N Z 13.
b N Z 8 since two COPD- and one NON-COPD-patient(s) received pr
c n Z 8 since one patient underwent polygraphy instead of polysomwas not included in any of these trials. In addition, only
a low number of PaCO2/PtcCO2-pairs were included in the
analysis.
In an initial daytime trial, the range in limits of agree-
ment was reported to be 11 mmHg in 26 PaCO2/NPPV. Values for mean  standard deviation or median with
OPD (N Z 9) Difference of mean 95% CI p-value
0e1.1) NF 0.002
7.8e23.2) NF 0.023
5e5.0) NF 0.591
4.8e20.5) NF 0.654
1e1.3)b NF 0.011
 47.7c 82.9 to 85.9 0.976
7.1e84.5)c NF 0.259
.5e38.5)c NF 0.478
16.8c 14.9 to 18.9 0.809
6.8c 10.0 to 6.5 0.666
6.2c 11.0 to 3.8 0.321
10.3c 12.3 to 12.9 0.963
5e9.9) NF 0.189
2.5 1.8 to 3.2 0.587
5e10.4) NF 0.743
13.1 14.5 to 3.2 0.341
itive airway pressure, NF Z normality test failed, NPPV Z non-
ment sleep, REM Z rapid eye movement sleep, RRset Z preset
de), SaO2 Z oxygen saturation, TST Z total sleep time.
essure support ventilation.
nography.
Table 3 Continuous overnight PtcCO2-monitoring. Median (interquartile range) is given for all patients (NZ 24), irrespective
of the underlying disease.
SenTec DM TCM4-TINA TOSCA500 p-value (RM-ANOVA)
Technical Drift (mmHg) 0.7 (0.2 to 1.7) 4.0 (5.0 to 2.0) 4.0 (6.0 to 2.5) <0.001
Mean of overnight PtcCO2 (mmHg) 48.5 (42.4e50.6) 47.9 (43.6e59.0) 47.8 (42.9e49.8) 0.718
Standard deviation of overnight
PtcCO2 (mmHg)
2.5 (1.9e3.0) 3.2 (2.3e4.0) 2.4 (2.1e3.0) 0.121
PtcCO2 Z transcutaneous partial pressure of carbon dioxide.
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13 In a further 8-h-daytime-study the range in
limits of agreement was 15 mmHg (28 PaCO2/
PtcCO2epairs).
31 Furthermore, twelve patients were
analyzed over a 40min period of daytime NPPV. Here, the
analysis of 48 pairs of values revealed a 12 mmHg range in
limits of agreement.33 The sole overnight study assessed
the first 5 h of the night with two different PtcCO2-monitors
in ten NPPV patients.32 Unfortunately, no comparison
according to the methods proposed by Bland and Altman45
was performed in that study. In clear contrast, the
present study is the first to use modern PtcCO2-monitoring
techniques to describe complete overnight PtcCO2-moni-
toring, with high-standard Bland and Altman statistical
analysis. Thereby, the range in limits of agreement was
dependent on the device being used, with the lowest range
value of 11.4 mmHg from the SenTec DM monitor deemed
acceptable for the purpose of overnight monitoring of
alveolar ventilation in patients with chronic HRF.
In most of the previous studies method comparison
revealed inconsistent results when comparing hypercapnia
to normocapnic conditions.31e33 The current study did not
focus on acute ventilatory failure or extremely hypercapnicTable 4 Correlation analysis and method comparison of PtcCO2/
for all patients (N Z 24), irrespective of the underlying disease.
SenTec DM
PaCO2 versus drift-uncorrected
PtcCO2
Pairs of values (N) 93
Pearson correlation coefficient
(R), p-value
R Z 0.943, p < 0.001
Mean of the difference (mmHg) 1.0
Limits of agreement (range)
(mmHg)
4.7 to 6.7 (11.4)
Mean of the difference
>7.5 mmHg
1.1%
PaCO2 versus drift-corrected
PtcCO2
software based
Pairs of values (N) 90
Pearson correlation coefficient
(R), p-value
R Z 0.946, p < 0.001
Mean of the difference (mmHg) 0.8
Limits of agreement (range)
(mmHg)
4.9 to 6.5 (11.4)
Mean of the difference
>7.5 mmHg
1.1%
PaCO2 Z arterial partial pressure of carbon dioxide, PtcCO2 Z transcpatients. However, in contrast to the afore mentioned
findings,31e33 the present study demonstrated that method
comparison was not inferior in hypercapnic values above
50mmHg suggesting an improvement of the technology in
the hypercapnic range. Furthermore, it remains speculative
if the current findings are transferable to extremely obese
patients suffering from obesity hypoventilation syndrome,
which are suggested to be the major subgroup receiving
NPPV in the future.7 Adipose tissue may have an impact on
PtcCO2-measurment. However, since previous studies
7,14,33
including more obese patients reported similarly positive
results in PtcCO2-monitoring it is likely that monitoring of
more obese patients is feasible with a comparable quality.
In addition, pairs of values outside the clinically
acceptable range of >7.5 mmHg28 were rare in two of the
applied monitors (SenTec DM 1% and TOSCA500 2% for drift-
uncorrected PtcCO2 values, respectively). This is in
contrast with an earlier intensive care unit study, where
19% of measured pairs were beyond this range.28 These
findings indicate that PtcCO2-monitoring is a robust method
for nocturnal application. Although the present study did
not aim to directly compare modern and older techniquesPaCO2-pairs at 11 pm, 2 am, 5 am and 7 am. Results are given
TCM4-TINA TOSCA500
88 92
R Z 0.740, p < 0.001 R Z 0.901, p < 0.001
1.5 0.8
15.6 to 12.5 (28.1) 6.8 to 8.3 (15.1)
27.3% 2.2%
calculated calculated
80 92
R Z 0.775, p < 0.001 R Z 0.922, p < 0.001
3.3 1.6
15.8 to 9.3 (25.1) 8.4 to 5.2 (13.6)
28.8% 4.3%
utaneous partial pressure of carbon dioxide.
Figure 1 Range of overnight carbon dioxide measurements
of PaCO2 and simultaneously monitored PtcCO2 reflecting
intermittent time spots at 11pm, 2am, 5am and 7am (N Z 24;
RM-ANOVA, p Z 0.003). PaCO2 Z arterial partial pressure of
carbon dioxide, PtcCO2 Z transcutaneous partial pressure of
carbon dioxide by SenTec DM, TCM4-TINA and TOSCA500.
Figure 2 Range of overnight carbon dioxide measurements
reflecting continuous transcutaneous monitoring (N Z 24; RM-
ANOVA, p < 0.001). PaCO2Z arterial partial pressure of carbon
dioxide, PtcCO2 Z transcutaneous partial pressure of carbon
dioxide by SenTec DM, TCM4-TINA and TOSCA500.
Figure 3 Overnight trend of PaCO2 (grey boxes) and PtcCO2
(solid line represents SenTec DM, interrupted line represents
TCM4-TINA, and dotted line represents TOSCA500) during non-
invasive positive pressure ventilation in a 34-year old patient
with congenital central hypoventilation syndrome showing
nighttime fluctuations of PCO2. The sensors were disconnected
from the patient between 6.30am and 7am for SenTec DM and
TOSCA500. PaCO2Z arterial partial pressure of carbon dioxide,
PtcCO2 Z transcutaneous partial pressure of carbon dioxide.
148 J.H. Storre et al.of PtcCO2-monitoring, the improvements in the stability
and reliability of PtcCO2-monitoring are likely attributed to
further technical refinements of the monitors.
It is well accepted that alveolar ventilation varies during
sleep in chronic HRF patients.5,34,46 Thereby, previous
studies have explicitly demonstrated that when NPPV is
applied during sleep, inspiratory, expiratory and leak
volumes vary substantially in individual
patients.7,12,22,23,47,48 Accordingly, the current study has
shown that the range of overnight PCO2 is higher when
assessed by all three continuous PtcCO2-monitors (Fig. 2)
compared to intermittent PCO2 assessment (Fig. 1), even if
ABG is performed four times during night, which is more
frequent than what is usually done in clinical prac-
tice.3,9,10,12,22,32,49 In line with these findings considerable
nighttime fluctuations of PCO2 due to various events as
given in Fig. 3 are only detectable by a continuous assess-
ment as given by PtcCO2 and would have been missed
relying on single morning blood gas analysis. Thus, there is
clear evidence that continuous monitoring of alveolar
ventilation using PtcCO2-monitoring is by far more
comprehensive than the single, random assessments
provided by intermittent PaCO2-measurments. In addition,
while intermittent ABG is invasive and sleep-disrupting,9
PtcCO2-monitoring is not likely to affect sleep quality
because it is non-invasive; once the sensor has been
adjusted prior to falling asleep, there is no need for specific
maneuvers during night. Based on these considerations and
also on the increasing reliability and stability of PtcCO2-
monitoring, the current authors propose PtcCO2-monitoring
to be the preferred method for monitoring alveolar venti-
lation during nocturnal NPPV in chronic HRF patients.
However, in contrast to SenTec DM and TOSCA500, the
TCM4-TINA monitor displayed expanded individual ranges
and wider limits of agreement for PtcCO2-monitoring
compared to PaCO2. This might be attributed to the sensor
temperature of 42 C, since higher temperatures were
recently reported to produce more acceptable limits of
agreement for the TCM4-TINA compared to PaCO2.
27,33,40While higher temperatures might be reasonable for short-
term PtcCO2-monitoring, such as during endoscopies,
17,50
higher sensor temperatures can cause cutaneous side-
effects during longer application, which is unacceptable for
overnight sleep studies.17,20,31 In addition, differences in
sensor membrane and changing frequency might be
a reason for divergence comparing results of TCM4-TINA to
SenTec DM or TOSCA500.
For nighttime measurements of capillary ABG patients
were not actively woken. However, due to the procedure of
ABG sleep quality was very likely to be negatively affected
Transcutaneous PCO2 during nocturnal NPPV 149by arousals.9 Furthermore, a lag time of PtcCO2-monitoring
influencing method comparison to PaCO2 could not be
excluded. As we showed in a previous work, the PtcCO2
value monitored with a 2 min delay was the best predictor
of PaCO2 compared to the simultaneously and 5-min
delayed monitored PtcCO2 value.
14 However, PtcCO2
monitored simultaneously to PaCO2 is suggested to be
a good predictor as well,14 and it remains speculative if an
overnight study taking into account the lag time would lead
to further improvement in method comparison of PaCO2
and PtcCO2.
Any technical problems arising during PtcCO2-monitoring
were manageable throughout the study. Short-term, inter-
mittent sensor detachment with associated data loss was
evident once each with the SenTec DM and TOSCA500, and
three times with the TCM4-TINA. The higher incidence of
sensor detachment with the TCM4-TINA might be attributed
to differences in the sensor fixation rings. While the TCM4-
TINA is wound into the fixation ring, the SenTec DM and
TOSCA500 each use a click-on ring which allows free rota-
tion. Following the above mentioned divergence in results
of TCM4-TINA to SenTec DM and TOSCA500 a free sensor
rotation might be an advantage in method comparison of
PtcCO2 to PaCO2. However sensor reattachment following
complete sensor disconnection was rarely required, occur-
ring only once for each of the three transcutaneous moni-
tors. In addition, there was no need for recalibration of the
monitors during the night.
In conclusion, calibration drifts in transcutaneous PCO2
values and the differences between transcutaneous and
arterial PCO2 have been shown to be low when modern
monitors are used to assess transcutaneous PCO2. Thus,
overnight PtcCO2-monitoring has become a reliable and
robust tool for assessing alveolar ventilation during sleep in
chronic HRF patients receiving NPPV. Furthermore, PtcCO2-
monitoring is non-invasive, and provides a more complete
picture of nocturnal alveolar ventilation. Given that inter-
mittent nocturnal arterial blood gas analysis disrupts sleep
quality and provides only a highly selective account of
alveolar ventilation during the night, the time has now
come to consider modern, technically-improved trans-
cutaneous PCO2 monitoring as the new gold standard for
nocturnal monitoring of alveolar ventilation in chronic HRF
patients with NPPV.
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